利妥昔单抗治疗弥漫大B细胞淋巴瘤的临床观察

Clinic Observation on Diffuse Large B-cell Lymphoma Treated by Rituximab

摘要: 目的观察利妥昔单抗治疗弥漫性大B细胞淋巴瘤(DLBCL)的疗效和不良反应。方法采用R-CHOP-21方案对40例DLBCL患者进行联合化疗。结果治疗2周期后近期疗效评价，CR 15例（37.5%），PR 14例（35%），有效率（RR）为72.5%。在不良反应中，Ⅳ度皮疹和心律失常各1例。结论利妥昔单抗近期疗效好；在不良反应中，Ⅳ度皮疹和心律失常必须及时发现和治疗。

Abstract: ObjectiveTo observe the curative effect and drug adverse reaction of rituximab in treatment for diffuse large B-cell lymphoma (DLBCL). Methods R-CHOP-21 regimen was employed to 40 patients with DLBCL. ResultsThe curative effects of the short-term were 15(37.5%) cases of complete response(CR),14(35%) cases of partial response(PR) and response rate(RR) was 72.5%. In drug adverse reactions, skin rash or cardiac rhythm of degree Ⅳ was 1 case respectively. ConclusionThe rituximab showed strongly short-term effect with moderate adverse reaction degree Ⅳ of skin toxicity and cardiac rhythm had to be found early and treated immediately.